Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Retatrutide — page 2

28 records for Retatrutide, of which 7 are published trials.

Showing 0 records on this page

Records

28 documents · page 2 of 2

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
TRIUMPH-1-DDIprogramme recordRetatrutidePhase 1OngoingRandomised crossoverVery low
TRIUMPH-2-BODY-COMPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-3-BIOMARKERprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low
TRIUMPH-2-REGIONAL-JPprogramme recordRetatrutidePhase 3OngoingRandomised, double-blind, placebo-controlledVery low

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.